Abstract | OBJECTIVE: METHODS: RESULTS: Of the 29 patients with malignant cell types (granulosa cell, Sertoli-Leydig cell, and steroid cell tumors), 21 of the 28 patients (75%) available for follow-up had recurrence, with a mean follow-up of 86 months (95% CI, 36-157 months). The telomerase repeat amplification protocol assay had a sensitivity of 74% and specificity of 94% for malignancy. Patients with telomerase-positive tumors had a mean disease-free interval of 66.5 months; for those with telomerase-negative tumors the interval was 90 months. In addition, patients with telomerase-positive tumors were more likely to be dead from disease or alive with disease than those without telomerase activity, and they showed trends toward requiring a larger number of surgical procedures for the treatment of their disease. However, these trends were not statistically significant. CONCLUSION:
|
Authors | S C Dowdy, D J O'Kane, G L Keeney, J Boyd, K C Podratz |
Journal | Gynecologic oncology
(Gynecol Oncol)
Vol. 82
Issue 2
Pg. 257-60
(Aug 2001)
ISSN: 0090-8258 [Print] United States |
PMID | 11531276
(Publication Type: Journal Article)
|
Copyright | Copyright 2001 Academic Press. |
Chemical References |
- DNA-Binding Proteins
- Telomerase
|
Topics |
- DNA-Binding Proteins
- Disease-Free Survival
- Female
- Humans
- Neoplasm Recurrence, Local
(enzymology, pathology)
- Ovarian Neoplasms
(enzymology, pathology)
- Reverse Transcriptase Polymerase Chain Reaction
- Risk Factors
- Sex Cord-Gonadal Stromal Tumors
(enzymology, pathology)
- Telomerase
(metabolism)
|